Nephrology

Erythropoietin for CKD Anemia song

Listen to the preview here. The full song is free on YouTube.

Erythropoietin for CKD Anemia

Full song on YouTube ↗

Key points in this song10

Erythropoietin (EPO) is produced by peritubular fibroblasts in the renal cortex; CKD destroys these cells, causing normocytic, normochromic anemia due to decreased EPO synthesis.
Before initiating EPO therapy, iron deficiency must be corrected first — transferrin saturation should be >20% and ferritin >100 ng/mL; EPO will not work without adequate iron stores.
Recombinant EPO agents used in CKD include epoetin alfa and darbepoetin alfa; darbepoetin has a longer half-life due to extra sialic acid residues, allowing less frequent dosing.
The target hemoglobin when using ESAs (erythropoiesis-stimulating agents) in CKD is 10–11 g/dL; targeting >13 g/dL increases risk of stroke, MI, and thrombosis.
EPO binds the JAK2-STAT5 signaling pathway to stimulate proliferation and differentiation of erythroid progenitor cells in the bone marrow.
A classic presentation: a CKD patient on dialysis with fatigue, low hemoglobin, normal MCV, and low reticulocyte count — think EPO deficiency, not iron deficiency or B12 deficiency.
Pure red cell aplasia (PRCA) is a rare but serious complication of exogenous EPO therapy caused by anti-EPO antibodies; presents with sudden severe anemia and absent reticulocytes.
EPO therapy increases hemoglobin but also raises blood pressure and increases thrombotic risk — hypertension is the most common side effect of ESA therapy in CKD patients.
Dialysis patients require higher EPO doses than pre-dialysis CKD patients due to uremic inhibitors of erythropoiesis and increased chronic inflammation raising hepcidin levels.
Elevated hepcidin in CKD blocks ferroportin, trapping iron in macrophages and enterocytes — this functional iron deficiency blunts response to EPO even when total body iron is adequate.